Life science is always asking new questions. It’s essential to the discovery process.
We are specialists in autoimmunity, inflammatory diseases and oncology, providing tailored cell-based and immunoassays and dedicated laboratory solutions for biopharma companies and clinical diagnostic labs through our worldwide partner network.
Simply put, we can provide the answers that our customers need throughout the entire drug development value chain – from early discovery through the clinical phases – in addition to tools for effective patient diagnosis and monitoring.
By helping to push the boundaries in drug discovery and clinical diagnostics, we contribute to the improvement of patient care.
Svar means answers in Swedish. If you have questions, we can help you find the right answers. Ask us today.
As a global supplier and partner within drug discovery and clinical diagnostics, Svar Life Science has 28 years of experience serving the life science market with diagnostic laboratory services aimed at helping customers move forward in the drug development process and ensuring optimal treatment of patients by providing accurate assay solutions for the clinical diagnostic laboratory.
Our strong Scandinavian roots are embodied in a high-quality, responsive, people- and solution-focused business. Through mergers, acquisitions, in-house innovation, industry collaboration and knowledge exchange, we continue to find and harness the optimal solutions for improved patient care and accelerated drug development.
In 2018 Euro Diagnostica changed its name to Svar Life Science. Our new name, which means answers in Swedish, reflects our values and Scandinavian heritage, and positions us for doing business in life science.
In 2014 we acquired Danish life science company Biomonitor A/S adding the iLite® technology and cell-based reporter gene assays to the product portfolio. This addition enabled us to expand our offering to encompass the entire drug development value chain.
This included sales of iLite to biopharma and CROs, establishment of patient monitoring through lab developed tests in the US, and the building of a dedicated bioanalytical services unit.